Antolín-Amerigo Darío, Tabar Isabel A, Del Mar Fernández-Nieto Maria, Callejo-Melgosa Anna M, Muñoz-Bellido Francisco J, Martínez-Alonso José C, Méndez-Alcalde Jorge D, Reche Marta, Rodríguez-Trabado Ana, Rosado-Ingelmo Ana, Alonso-Gómez Alicia, Blanco-González Rosa, Alvarez-Fernandez José A, Botella Isabel, Valls Ana, Cimarra Mercedes, Blanco Carlos
Servicio de Enfermedades del Sistema Inmune-Alergia, Hospital Universitario Príncipe de Asturias, Departamento de Medicina, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain.
Complejo Hospitalario de Navarra, IdiSNA (Navarra Institute for Health Research), Pamplona, Spain.
Drugs Context. 2017 Nov 29;6:212309. doi: 10.7573/dic.212309. eCollection 2017.
Five-grass pollen tablet is an effective and well-tolerated therapy for patients with allergic rhinoconjunctivitis (ARC). This trial sought to determine the satisfaction and health-related quality of life (HRQoL) of patients undergoing this treatment.
This was a cross-sectional, multicentre, observational, naturalistic study, following a discontinuous pre- and co-seasonal five-grass pollen regimen over two seasons in Spain (2012, 2013). The HRQoL of the patients was measured with the specific Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) for adults, adolescent (AdolRQLQ), or paediatric (PRQLQ) patients. Treatment satisfaction was assessed by the Satisfaction Scale for Patients Receiving Allergen Immunotherapy (ESPIA) questionnaire. Patients/investigators were surveyed on beliefs and attitudes towards the five-grass pollen tablet. ARC evolution according to allergic rhinitis and its impact on asthma (ARIA) criteria and treatment adherence were evaluated.
Among the 591 ARC patients included, the mean (SD) HRQoL scores were 1.40 (1.1) in adults, 1.33 (1.1) in adolescents, and 1.15 (1.1) in children, indicating low levels of impairment (scale 0-6). ESPIA answers showed high levels of satisfaction, with an average score of 69.2 (scale 0-100). According to ARIA criteria, 88.2% of patients reported improvement of ARC. Moreover, this was accompanied by a reduced use of symptomatic medication. Adherence to treatment was estimated at 96.8%. In general, both patients and specialists exhibited a positive attitude towards five-grass pollen tablet treatment.
ARC patients treated with five-grass pollen tablet showed favourable levels of HRQoL and treatment satisfaction, with concomitant improvements in ARC and symptomatic medication use, which translated into high levels of treatment adherence and a positive attitude towards five-grass pollen tablet.
五草花粉片是治疗变应性鼻结膜炎（ARC）患者的一种有效且耐受性良好的疗法。本试验旨在确定接受该治疗的患者的满意度及健康相关生活质量（HRQoL）。
这是一项横断面、多中心、观察性、自然主义研究，在西班牙（2012年、2013年）两个季节采用间断的季前和季中五草花粉治疗方案。采用针对成人、青少年（AdolRQLQ）或儿童（PRQLQ）患者的特异性鼻结膜炎生活质量问卷（RQLQ）测量患者的HRQoL。通过接受变应原免疫治疗患者满意度量表（ESPIA）问卷评估治疗满意度。就患者/研究者对五草花粉片的信念和态度进行调查。根据变应性鼻炎及其对哮喘的影响（ARIA）标准评估ARC进展情况及治疗依从性。
纳入的591例ARC患者中，成人的平均（标准差）HRQoL评分为1.40（1.1），青少年为1.33（1.1），儿童为1.15（1.1），表明损伤程度较低（0 - 6分）。ESPIA答案显示满意度较高，平均得分为69.2（0 - 100分）。根据ARIA标准，88.2%的患者报告ARC有所改善。此外，这还伴随着对症药物使用的减少。治疗依从性估计为96.8%。总体而言，患者和专科医生对五草花粉片治疗均表现出积极态度。
接受五草花粉片治疗的ARC患者表现出良好的HRQoL水平和治疗满意度，ARC及对症药物使用均有改善，这转化为较高的治疗依从性以及对五草花粉片的积极态度。
